• CapsoVision posted a net loss of $7.03 million, widening 31% from year-ago, as operating loss deepened 32% to $7.09 million.
• Revenue was flat at $2.79 million, while gross margin fell 6 percentage points to 48% due to higher customs and tariffs tied to changes in U.S. trade policy.
• Research and development expense climbed 43% to $4.44 million on higher clinical trial costs and non-recurring engineering services under a development agreement with Canon Inc.
• Cash and cash equivalents totaled $17.9 million, with management flagging substantial doubt about its ability to continue as a going concern within one year.
• CapsoCam Colon second-generation pivotal study enrolled over 600 patients toward a planned 510(k) submission in Q3 2026, while FDA clearance for an AI-enabled CapsoCam Plus update is expected by mid-2026 with commercialization planned shortly thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capso Vision Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001378325-26-000021), on May 14, 2026, and is solely responsible for the information contained therein.